| lacosamide / Generic mfg. |
NCT01796938: Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Single Dose Lacosamide in Subjects With Renal Impairment Compared to Healthy Subjects |
|
|
| Completed | 1 | 40 | Europe | Lacosamide tablet, Vimpat | UCB BIOSCIENCES GmbH | Healthy, Renal Impairment | 11/04 | 11/04 | | |
NCT01450111: To Evaluate the Pharmacokinetics and Safety/Tolerability of Lacosamide in 3 Dosages in Healthy Male Korean Subjects |
|
|
| Completed | 1 | 51 | RoW | Lacosamide, Vimpat®, Placebo | UCB Pharma | Epilepsy | 02/09 | 02/09 | | |
NCT01375387: Three-way-cross-over Study to Evaluate Safety and Pharmacokinetics of Lacosamide in Healthy Japanese and Chinese Males |
|
|
| Completed | 1 | 33 | Europe | Lacosamide, Vimpat®, Placebo 3, Placebo 4, Placebo 2 | UCB Pharma | Healthy Volunteers | 06/11 | 06/11 | | |
NCT01526083: Effect of Lacosamide 200 mg Twice a Day (Bid) on Single Dose Warfarin 25 mg in Healthy Males |
|
|
| Completed | 1 | 16 | Europe | Lacosamide, Vimpat, Warfarin, Coumadin | UCB Pharma | Healthy Volunteers | 03/12 | 03/12 | | |
NCT01530386: A Multicenter, Open-label Study to Determine the Effects of Lacosamide on Sleep in Healthy Subjects |
|
|
| Completed | 1 | 25 | US | Lacosamide | UCB Pharma | Healthy Subjects | 07/12 | 07/12 | | |
NCT01986608: Bioavailability/Bioequivalence Study Between Lacosamide Tablet and Solution for Infusion in Healthy Japanese Subjects |
|
|
| Completed | 1 | 26 | Europe | Lacosamide infusion, Vimpat, Lacosamide oral | UCB Pharma SA | Healthy Volunteers | 12/13 | 12/13 | | |
NCT01530022: Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects |
|
|
| Completed | 1 | 60 | US | Lacosamide (LCM), Vimpat, Carbamazepine Immediate Release (CBZ-IR), Tegretol IR | UCB Pharma | Healthy | 01/14 | 01/14 | | |
2014-002629-36: A study to investigate the pharmacokinetics in children (aged 1 month to 17 years) with epilepsy, prescribed lacosamide. |
|
|
| | 1 | 32 | US | Lacosamide, Film-coated tablet, Oral solution, Vimpat | UCB Biosciences, Inc, UCB Biosciences, Inc | Epilepsy, Epilepsy, Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT02972125: A Study to Demonstrate the Bioequivalence of Lacosamide Tablets and Dry Syrup in Healthy Male Japanese Subjects |
|
|
| Completed | 1 | 24 | Europe | Lacosamide (LCM) tablet, Lacosamide (LCM) dry syrup | UCB Biopharma S.P.R.L. | Healthy Volunteers | 03/17 | 03/17 | | |
NCT03086382: A Study to Investigate the Bioequivalence of Lacosamide Tablet (200mg) and Syrup (10mg/ml) in Healthy Chinese Male Subjects |
|
|
| Completed | 1 | 24 | RoW | Lacosamide (LCM) tablet, Lacosamide (LCM) syrup | UCB Biopharma S.P.R.L. | Healthy Male Volunteers | 03/17 | 03/17 | | |
NCT03204474: A Study to Investigate the Bioequivalence of Lacosamide 200mg Administered as Intravenous Solution and Oral Tablet in Healthy Chinese Male Subjects |
|
|
| Completed | 1 | 30 | RoW | Lacosamide (LCM) tablet, Vimpat, Lacosamide (LCM) solution for infusion | UCB Biopharma S.P.R.L. | Healthy Male Chinese Volunteers | 07/17 | 07/17 | | |
NCT03271528: Lacosamide Effects on Alcohol Self Administration and Craving in Heavy Drinkers |
|
|
| Completed | 1 | 66 | US | Lacosamide, Vimpat, Placebo oral capsule | Boston Medical Center, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Use Disorder | 08/20 | 08/20 | | |
STTEPP, NCT05603702: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis |
|
|
| Recruiting | 1 | 24 | US | Lacosamide, VIMPAT | Indiana University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Chronic Pain, Chronic Pain Syndrome, Chronic Pancreatitis, Hyperalgesia, Opioid Use Disorder, Opioid-Related Disorders, Opioid Dependence, Chronic Abdominal Pain, ERCP, Pancreatic Surgery | 03/25 | 03/25 | | |
